Perinatal Clinical Pharmacology: Optimizing Pharmacotherapy for Pregnant Women, Their Fetuses and Infants

Author(s): Karel Allegaert, John N. van den Anker

Journal Name: Current Pharmaceutical Design

Volume 25 , Issue 5 , 2019


Become EABM
Become Reviewer
Call for Editor

[1]
Van Calsteren K, Gersak K, Sundseth H, et al. Position statement from the European Board and College of Obstetrics & Gynaecology (EBCOG): The use of medicines during pregnancy – call for action. Eur J Obstet Gynecol Reprod Biol 2016; 201: 189-91.
[2]
Ito S. Mother and child: medication use in pregnancy and lactation. Clin Pharmacol Ther 2016; 100: 8-11.
[3]
Sahin L. Center for Drug Evaluation and Research, Office of New Drugs, U.S. Food and Drug Administration. https://wayback.archive-it.org/7993/20170112082410/http:/www.fda.gov/downloads/Drugs/NewsEvents/UCM399660.pdfaccessed February. 162019;
[5]
Ceulemans M, Lupattelli A, Nordeng H, Odalovic M, Twigg M, Foulon V. Medication-taking during pregnancy: opportunities for community pharmacists? Curr Pharm Des 2018; 25(5): 469-82.
[6]
Dallmann A, Mian P, van den Anker J, Allegaert K. Clinical pharmacokinetic studies in pregnant women and the relevance of pharmacometric tools. Curr Pharm Des 2018; 25(5): 483-95.
[7]
Bouazza N, Foissac F, Hirt D, et al. Methodological approaches to evaluate fetal drug exposure. Curr Pharm Des 2018; 25(5): 496-504.
[8]
Hitzerd E, Broekhuizen M, Neuman RI, et al. Human placental vascular reactivity: implications for the treatment of pre-eclampsia. Curr Pharm Des 2018; 25(5): 505-27.
[9]
Ito S. Emerging research paradigm for infant drug exposure through breast milk. Curr Pharm Des 2018; 25(5): 528-33.
[10]
Ventrella D, Forni M, Bacci ML, Annaert P. Non-clinical models to determine drug passage into human breast milk. Curr Pharm Des 2018; 25(5): 534-48.
[11]
Allegaert K, Mian P, van den Anker JN. Developmental pharmacokinetics in neonates: maturational changes and beyond. Curr Pharm Des 2017; 23: 5769-78.
[12]
Michelet R, van Bocxlaer JV, Vermeulen A. PBPK in preterm and term neonates: A review. Curr Pharm Des 2017; 23: 5943-54.
[13]
Philips JM, van den Anker JN, Ahmadzia H. Next generation medical management of postpartum hemorrhage. Curr Pharm Des 2018; 25(5): 549-55.
[14]
Hodel EM, Marzolinin C, Waitt C, Rakhamina N. Pharmacokinetics, placental and breastmilk transfer of antiretroviral drugs in pregnant and lactating women living with HIV. Curr Pharm Des 2018; 25(5): 556-76.
[15]
Lamont RF, Jorgensen JS. Safety and efficacy of tocolytics for the treatment of spontaneous preterm labour. Curr Pharm Des 2018; 25(5): 577-92.
[16]
Reznik SE. Editorial: novel pharmacotherapeutic targets and emerging approaches to prevent preterm birth. Curr Pharm Des 2017; 23: 6097.
[17]
Hrabalkova L, Takahashi T, Kemp MW, Stock SJ. Antenatal corticosteroids for fetal lung maturity – too much of a good thing? Curr Pharm Des 2018; 25(5): 593-600.
[18]
Russo FM, Debie F, Hodges R, Flake A, Deprest J. Sildenafil for antenatal treatment of congenital diaphragmatic hernia: From bench to bedside. Curr Pharm Des 2018; 25(5): 601-8.
[19]
McCune SK, Mulugeta YA, Baer GR. Collaboration in regulatory science to facilitate therapeutic development for neonates. Curr Pharm Des 2017; 23: 5801-4.
[20]
Roca C, Sahin L, Yao L. Collaboration in regulatory science to facilitate therapeutic development for pregnant women. Curr Pharm Des 2018; 25(5): 609-14.
[21]
Gyselaers W, Lanssens D, Perry H, Khalil A. Mobile health applications for prenatal assessment and monitoring. Curr Pharm Des 2018; 25(5): 615-23.
[22]
Izmailova ES, Wagner JA, Perakslis ED. Wearable devices in clinical trials: Hype and hypothesis. Clin Pharmacol Ther 2018; 104: 42-52.


free to download

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 25
ISSUE: 5
Year: 2019
Published on: 02 June, 2019
Page: [467 - 468]
Pages: 2
DOI: 10.2174/138161282504190516090723

Article Metrics

PDF: 32
HTML: 7
EPUB: 1
PRC: 1